Logan Coy Related postsA Multicenter, Randomized, Double-Blind, Adaptive Phase 2/3 Study of EIK1001 and Pembrolizumab vs Placebo and Pembrolizumab as First-Line Therapy in Advanced MelanomaSeptember 11, 2026A Phase 1b study of the pharmacokinetics, safety, and efficacy of orally administered HQP1351 in subjects with refractory chronic myeloid leukemiaSeptember 11, 2026A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer After Prior ChemotherapySeptember 11, 2026 Previous postAn Open-Label, Multicenter, Multi-Arm Phase 1 Study of ADU-1805 in Adults with Advanced Solid TumorsNext postA Phase 1/2a, Open-Label Study of SA53-OS, an MDM2 Inhibitor, in Locally Advanced or Metastatic p53 Wild-Type Solid Tumors